HARMONY BIOSCIENCES HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $21.90 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-04
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $23.38, a 8.31% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $25.50.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-03-31 was $11.99.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $24.08, a 16.44% increase from fiscal 2024.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $20.68.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2019 was $3.45.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $21.90 10-Q · filed 2026-08-04 | ||||
| 2026-03-31 | $23.38 10-Q · filed 2026-05-07 | ||||
| 2025-12-31 | $24.08 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $36.24 10-Q · filed 2025-11-04 | ||||
| 2025-06-30 | $24.24 10-Q · filed 2026-08-04 | ||||
| 2025-03-31 | $25.50 10-Q · filed 2026-05-07 | ||||
| 2024-12-31 | $20.68 10-K · filed 2026-02-24 | ||||
| 2021-09-30 | $12.52 10-Q · filed 2021-11-09 | ||||
| 2021-06-30 | $12.24 10-Q · filed 2021-08-10 | ||||
| 2021-03-31 | $11.99 10-Q · filed 2021-05-11 | ||||
| 2020-12-31 | $10.06 10-Q · filed 2021-11-09 | ||||
| 2020-09-30 | $9.39 10-Q · filed 2020-11-12 | ||||
| 2019-12-31 | $3.45 10-K · filed 2021-03-25 | $3.38 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |